Ricardo D. Parrondo, MD

Mayo Clinic

N/A

Poster(s):

• 1502 - Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi

• 1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study

• 1601 - Central Nervous System Involvement in Patients with Richter Transformation